{
  "ticker": "VRTX",
  "company_name": "Vertex Pharmaceuticals Incorporated",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT02797132",
      "title": "Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Cystic Fibrosis",
      "start_date": "2016-05",
      "completion_date": "2017-09",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT06887959",
      "title": "A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries",
      "status": "COMPLETED",
      "phase": "PHASE4",
      "condition": "Acute Pain",
      "start_date": "2025-03-27",
      "completion_date": "2025-11-10",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT05791201",
      "title": "A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Type 1 Diabetes",
      "start_date": "2023-05-16",
      "completion_date": "2026-05-29",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT01790100",
      "title": "A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Na\u00efve Subjects With Chronic Hepatitis C",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Chronic Hepatitis C",
      "start_date": "2013-02-28",
      "completion_date": "2014-06-30",
      "enrollment": 0,
      "sponsor": "Alios Biopharma Inc."
    },
    {
      "nct_id": "NCT02412111",
      "title": "A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Cystic Fibrosis",
      "start_date": "2015-06",
      "completion_date": "2017-09",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT03304028",
      "title": "MUCOviscidose EXacerbation Outils Connect\u00e9s Education Th\u00e9rapeutique",
      "status": "TERMINATED",
      "phase": "NA",
      "condition": "Cystic Fibrosis",
      "start_date": "2017-10-20",
      "completion_date": "2020-06-18",
      "enrollment": 0,
      "sponsor": "Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale, France"
    },
    {
      "nct_id": "NCT05535959",
      "title": "A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Cystic Fibrosis",
      "start_date": "2022-09-15",
      "completion_date": "2022-11-09",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT05541471",
      "title": "A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Pain",
      "start_date": "2022-09-22",
      "completion_date": "2023-04-28",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT05579431",
      "title": "A Phase 1, First-in-human Study of VX-634",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Alpha 1-Antitrypsin Deficiency",
      "start_date": "2022-10-13",
      "completion_date": "2023-11-13",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    },
    {
      "nct_id": "NCT05951205",
      "title": "Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, \u03b2S/\u03b2C Genotype",
      "status": "NOT_YET_RECRUITING",
      "phase": "PHASE3",
      "condition": "Sickle Cell Disease",
      "start_date": "2027-07-31",
      "completion_date": "2033-12-31",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE3": 18,
      "PHASE4": 1,
      "PHASE1, PHASE2": 1,
      "PHASE2": 11,
      "NA": 1,
      "PHASE1": 13,
      "": 3,
      "PHASE2, PHASE3": 2
    },
    "by_status": {
      "COMPLETED": 36,
      "ACTIVE_NOT_RECRUITING": 2,
      "TERMINATED": 5,
      "NOT_YET_RECRUITING": 1,
      "RECRUITING": 3,
      "UNKNOWN": 1,
      "WITHDRAWN": 1,
      "ENROLLING_BY_INVITATION": 1
    },
    "active_trials": 6,
    "completed_trials": 36,
    "conditions": [
      "Acute Leukemia, Chronic Leukemia, Multiple Myeloma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Waldenstrom's Macroglobulinemia",
      "Acute Pain",
      "Alpha 1-Antitrypsin Deficiency",
      "Alpha-1 Antitrypsin Deficiency",
      "Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies",
      "Beta-Thalassemia, Thalassemia, Hematologic Diseases, Genetic Diseases, Inborn, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Anemia",
      "Chronic Hepatitis C",
      "Cystic Fibrosis",
      "Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia",
      "Diabetic Peripheral Neuropathic Pain",
      "Diabetic Peripheral Neuropathy",
      "Drug Interactions",
      "Epilepsy",
      "HCV Infection",
      "Hepatitis C",
      "Infection",
      "Myotonic Dystrophy Type 1 (DM1)",
      "Pain",
      "Sickle Cell Disease",
      "Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hemoglobinopathies, Hematological Diseases",
      "Type 1 Diabetes"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:22:51.530160",
    "search_query": "Vertex Pharmaceuticals Incorporated",
    "url": "https://clinicaltrials.gov/search?term=Vertex+Pharmaceuticals+Incorporated"
  }
}